Market News

Breaking: Citigroup Keeps $28 Target Price On Audentes Therapeutics (BOLD) Shares, Keeps Their Original “Neutral” Rating

Breaking: Citigroup Keeps $28 Target Price On Audentes Therapeutics (BOLD) Shares, Keeps Their Original “Neutral” Rating

Audentes Therapeutics (BOLD) Rating Reaffirmed EU: In an analyst note revealed to clients and investors on Monday, 10 December, Citigroup reconfirmed their “Neutral” rating on Audentes Therapeutics (BOLD) shares. They now have a $28 PT on the company. Citigroup’s target indicates a potential upside of 20.07 % from the company’s […]

Blink Charging (BLNK) Sees Coverage Initiated By H.C. Wainwright with a $5 Price

Why Has H.C. Wainwright Given Blink Charging (BLNK) a $5 Price Target H.C. Wainwright analyst started coverage with a “Buy” rating on Blink Charging (BLNK) today and set a price target of $5. The company’s shares opened today at 2.07. The stock decreased 1.90% or $0.04 during the last trading […]

Citigroup Reaffirmed Big Lots (NYSE:BIG) As a “Buy”; They Now Have a Price Objective Of $36

Citigroup Reaffirmed Big Lots (NYSE:BIG) As a “Buy”; They Now Have a Price Objective Of $36

Investors sentiment decreased to 0.77 in Q2 2018. Its down 0.20, from 0.97 in 2018Q1. It turned negative, as 69 investors sold Big Lots, Inc. shares while 82 reduced holdings. 37 funds opened positions while 80 raised stakes. 45.33 million shares or 9.08% less from 49.86 million shares in 2018Q1 […]

Citigroup Maintains Bunge (NYSE:BG) As a Buy; They Now Have a Target Of $80

Citigroup Maintains Bunge (NYSE:BG) As a Buy; They Now Have a Target Of $80

Investors sentiment decreased to 0.9 in Q2 2018. Its down 0.25, from 1.15 in 2018Q1. It fall, as 51 investors sold Bunge Limited shares while 114 reduced holdings. 47 funds opened positions while 102 raised stakes. 108.80 million shares or 0.40% more from 108.36 million shares in 2018Q1 were reported. […]

Is ACADIA Pharmaceuticals (NASDAQ:ACAD) Finally Worth Your Time? What Does Canaccord Genuity Think?

Is ACADIA Pharmaceuticals (NASDAQ:ACAD) Finally Worth Your Time? What Does Canaccord Genuity Think?

Investors sentiment increased to 1.22 in 2018 Q2. Its up 0.33, from 0.89 in 2018Q1. It is positive, as 31 investors sold ACADIA Pharmaceuticals Inc. shares while 43 reduced holdings. 35 funds opened positions while 55 raised stakes. 114.30 million shares or 4.25% less from 119.37 million shares in 2018Q1 […]

Is Welltower (WELL) a Buy or a Sell? What Does Scotiabank Think?

Is Welltower (WELL) a Buy or a Sell? What Does Scotiabank Think?

Why Has Scotiabank Given Welltower (WELL) a $74 Price Target EU: Welltower (WELL) coverage was started with a key ‘”Sector Perform”‘ rating as well as a $74 target price per share at Scotiabank. The target price per share by Scotiabank gives upside of 1.36 % from the previous stock close. […]

What Can We Expect From R1 RCM (RCM) After Citigroup’s Latest Coverage?

What Can We Expect From R1 RCM (RCM) After Citigroup’s Latest Coverage?

Why Has Citigroup Given R1 RCM (RCM) a $20 Price Target Citigroup analyst began coverage with a “Buy” rating on R1 RCM (RCM) today and set a price target of $20. The company’s shares opened today at 8.99. R1 RCM Inc. (NASDAQ:RCM) Ratings Coverage Among 2 analysts covering R1 RCM […]

How Will Anglogold Ashanti (NYSE:AU) Stock React To New Rating Coverage byBMO Capital?

How Will Anglogold Ashanti (NYSE:AU) Stock React To New Rating Coverage byBMO Capital?

Why Has BMO Capital Given Anglogold Ashanti (NYSE:AU) a $11 Price Target BMO Capital analyst has started coverage with a “Market Perform” rating on Anglogold Ashanti (NYSE:AU) today and set a price target of $11. The company’s shares opened today at 11.1. The stock decreased 1.60% or $0.18 during the […]

Key Analysts at Liberum Capital Reconfirmed their ‘”Buy”’ rating for Van Elle Holdings (LON:VANL) Shares Today. Their Target is Set to GBX 100.00

Van Elle Holdings (LON:VANL) Rating Reaffirmed The financial company has just set a price target of GBX 100.00 on Van Elle Holdings (LON:VANL) shares. This is 29.87 % from the current price. In an analyst note sent to investors on Monday morning, Liberum Capital reiterated their “Buy” rating on shares […]

ACADIA Pharmaceuticals (ACAD) Reaching An Inflection Point; Canaccord Initiates Shares At Hold with $23.0 target

ACADIA Pharmaceuticals (ACAD) Reaching An Inflection Point; Canaccord Initiates Shares At Hold with $23.0 target

Investors sentiment increased to 1.22 in 2018 Q2. Its up 0.33, from 0.89 in 2018Q1. It increased, as 31 investors sold ACADIA Pharmaceuticals Inc. shares while 43 reduced holdings. 35 funds opened positions while 55 raised stakes. 114.30 million shares or 4.25% less from 119.37 million shares in 2018Q1 were […]